ImmunoScape has continued its COVID-19 collaboration with NIAID and the Johns Hopkins University to better understand if the CD8+ T-cell responses from COVID-19...
Mar 9, 2021
Helsinki, Finland, 9 March 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases,...
Feb 22, 2021
SINGAPORE and SAN DIEGO – February 23, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...
Jan 28, 2021
SINGAPORE and SAN DIEGO – January 28, 2021 – ImmunoScape, a biotech company with an immunomics-based technology platform that provides novel insights into the human...
Jan 26, 2021
ImmunoScape is thrilled to announce its collaboration with Johns Hopkins University/NIAID to deeply profile the SARS-CoV-2-specific CD8 T cell response in COVID-19...
Dec 11, 2020
ImmunoScape won Singapore's most prestigious Emerging Enterprise Award organized by Business Times and OCBC Bank. Emerging Enterprise Award honors the bold ambition of...
Oct 20, 2020
In the fight against COVID-19, ImmunoScape is joining forces with Dr. Patrick Reeves, Team Leader at the Massachusetts General Hospital Vaccine & Immunotherapy...
Aug 20, 2020
As part of a collective effort in fighting COVID-19, ImmunoScape is collaborating with Arcturus Therapeutics, a developer of RNA therapeutics for treatment and...
Aug 11, 2020
The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies...